Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2010
08/12/2010US20100204125 Genetic alterations associated with cancer
08/12/2010US20100204124 Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
08/12/2010US20100204123 Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
08/12/2010US20100204122 Treatment of osteoporosis in peri- and post- menopausal women with hepcidin
08/12/2010US20100204121 Dietary supplements containing terpenoid acids of maslinic acid or oleanolic acid and process for enhancing muscle mass in mammals
08/12/2010US20100204120 Trimeric hiv fusion inhibitors for treating or preventing hiv infection
08/12/2010US20100204119 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5h)-yl phenyl derivatives
08/12/2010US20100204118 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
08/12/2010US20100204117 Cgrp as a therapeutic agent
08/12/2010US20100204116 Use of calcitonin as anti-angiogenic agent
08/12/2010US20100204115 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents
08/12/2010US20100204114 Use of a galanin peptide as a therapeutic agent
08/12/2010US20100204113 Use of stresscopin-related peptide as a therapeutic agent
08/12/2010US20100204112 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
08/12/2010US20100204111 Astressin and beta- endorphin for use as therapeutic agents
08/12/2010US20100204110 Use of a peptide as a therapeutic agent
08/12/2010US20100204109 Use of c-type natriuretic peptide, alone or in combination with neuropeptide af, as a therapeutic agent
08/12/2010US20100204108 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents
08/12/2010US20100204107 Use of urodilatin as a therapeutic agent
08/12/2010US20100204106 Use of GIP for the Treatment of Disorders Associated with Dysfunctional Synaptic Transmission
08/12/2010US20100204105 Glucagon analogues
08/12/2010US20100204104 Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
08/12/2010US20100204103 Helical synthetic peptides that stimulate cellular cholesterol efflux
08/12/2010US20100204102 Hybrid gel comprising chemically crosslinked hyaluronic acid derivative and pharmaceutical composition comprising the same
08/12/2010US20100204101 Method and product for treatment and/or prevention of complications of prematurity
08/12/2010US20100204100 Biological agents active in central nervous system
08/12/2010US20100204099 Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
08/12/2010US20100204098 Peptides with antifungal activity
08/12/2010US20100204097 Therapeutic methods using a thymus peptide
08/12/2010US20100204096 Treatment of inflammation, demyelination and neuronal/axonal loss
08/12/2010US20100204095 Genetically Modified TFPI And Method Of Making The Same
08/12/2010US20100204094 Diuretic and natriuretic polypeptides
08/12/2010US20100204093 Use of heat shock activators for tissue regeneration
08/12/2010US20100204092 Activin-actrii antagonists and uses for increasing red blood cell levels
08/12/2010US20100204091 SIVA Ubiquitination and/or Degradation-Related Activity and Modulators Thereof
08/12/2010US20100204090 Use of a peptide as a therapeutic agent
08/12/2010US20100204089 Phosphorylated pyrone analogs and methods
08/12/2010US20100204088 Cyclic Peptide Antitumor Agents
08/12/2010US20100204087 Tribonectins
08/12/2010US20100204086 Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
08/12/2010US20100204085 Structure-based design of peptide inhibitors of amyloid fibrillation
08/12/2010US20100204051 Hereditary Hemochromatosis Gene
08/12/2010US20100203628 Novel modified galectin 9 proteins and use thereof
08/12/2010US20100203617 Use of saccharomyces cerevisiae erg4 mutants for expressing mammalian glucose transporters
08/12/2010US20100203589 Method for obtaining active beta-ngf
08/12/2010US20100203511 Retinoid metabolizing protein
08/12/2010US20100203180 Antimicrobial protein derived from podoviriedae bacteriophage specific to staphylococcus aureus
08/12/2010US20100203176 Method for reducing weight in a subject
08/12/2010US20100203168 Use of calcitonin, SERMs such as raloxifene, testosterone, estrogen, calcimimetics such as cinacalcet, RANKL inhibitors such as denosumab, and bisphosphonates such as risedronate
08/12/2010US20100203163 Injectable polymer-lipid blend for localized drug delivery
08/12/2010US20100203153 Sustained-release nanoparticle compositions and methods using the same
08/12/2010US20100203148 Encapsulation and Controlled Release of Small Molecules for Intracellular Delivery Using Thermally Responsive Nanocapsules
08/12/2010US20100203147 Viruses for the Treatment of Cellular Proliferative Disorders
08/12/2010US20100203146 Intermittent dosing strategy for treating rheumatoid arthritis
08/12/2010US20100203142 Amphiphilic compound assisted nanoparticles for targeted delivery
08/12/2010US20100203135 Skin Equivalent Culture
08/12/2010US20100203133 High drug load tablet
08/12/2010US20100203120 Pharmaceutical cyclosporin compositions
08/12/2010US20100203119 Pharmaceutical treatment process using chitosan or derivative thereof
08/12/2010US20100203111 G-substrate for the treatment and prevention of parkinson's disease
08/12/2010US20100203110 Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production
08/12/2010US20100203109 Methods and Compositions for Treating Melanoma
08/12/2010US20100203105 Method for administering insulin to the buccal region
08/12/2010US20100203103 Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
08/12/2010US20100203100 Antimicrobial accessory for an implantable medical device
08/12/2010US20100203099 Multi-domain amphipathic helical peptides and methods of their use
08/12/2010US20100203083 Mutated structural protein of a parvovirus
08/12/2010US20100203076 Complexes of rna and cationic peptides for transfection and for immunostimulation
08/12/2010US20100203075 Chlamydia antigens
08/12/2010US20100203066 Polymeric linkers containing pyridyl disulfide moieties
08/12/2010US20100203065 Human liver regeneration associated protein and the use thereof
08/12/2010US20100203064 Methods and compositions for modulating wound repair
08/12/2010US20100203063 Pestivirus species
08/12/2010US20100203061 Prevention and treatment of retinal ischemia and edema
08/12/2010US20100203056 Anti-pd-l1 antibodies and their use to enhance t-cell function
08/12/2010US20100203055 Hair regrowth promoter
08/12/2010US20100203053 Method and composition for treating immune complex associated disorders
08/12/2010US20100203052 Binding domain-immunoglobulin fusion proteins
08/12/2010US20100203049 Interleukin-10 Antibodies
08/12/2010US20100203044 Dr6 antagonists and uses thereof in treating neurological disorders
08/12/2010US20100203043 Treatment and diagnosis of metastatic prostate cancer with inhibitors of epidermal growth factor receptor (egfr)
08/12/2010US20100203042 Recombinant anti-vla4 antibody molecules
08/12/2010US20100203040 Genetic Products Which are Differentially Expressed in Tumors and Use Thereof
08/12/2010US20100203038 Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual
08/12/2010US20100203037 identifying a Glucose-dependent Insulinotropic Peptide (GIP) secretagogue; G protein-coupled receptor (GPCR); useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis
08/12/2010US20100203034 Methods for the treatment and prevention of diseases of biological conduits
08/12/2010US20100203032 Orlistat compositions
08/12/2010US20100203031 Method for enhancing the cleavage activity of i-crei derived meganucleases
08/12/2010US20100203030 Pharmaceutical formulation
08/12/2010US20100203029 Lysyl oxidase-like 1 (loxl1) and elastogenesis
08/12/2010US20100203028 Antimicrobial compositions
08/12/2010US20100203017 Cladribine Regimen for Treating Multiple Sclerosis
08/12/2010US20100203016 Pregnancy hormone combination for treatment of autoimmune diseases
08/12/2010US20100203015 Carba-nucleoside analogs for antiviral treatment
08/12/2010US20100203014 Zwitterionic buffered acidic peptide and protein formulations
08/12/2010US20100203013 Treating Hepatitis C Virus Infection
08/12/2010US20100203012 Iap bir domain binding compounds
08/12/2010US20100203011 Mammalian Cytokines; Related Reagents and Methods
08/12/2010US20100203010 Modulation of tumor microenvironment
08/12/2010US20100203009 Pathway for Th-17 Cell Development and Methods Utilizing Same
1 ... 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 ... 3163